

Incidence and Outcomes in Acute Kidney Injury: A Comprehensive Population-Based Study

Tariq Ali,* Izhar Khan,[†] William Simpson,[‡] Gordon Prescott,[§] John Townend,[§] William Smith,[§] and Alison MacLeod^{*}

Departments of ^{*}Medicine & Therapeutics and [§]Public Health, University of Aberdeen; Departments of [†]Nephrology and [‡]Biochemistry, Grampian Health Board, Aberdeen, United Kingdom

Epidemiological studies of acute kidney injury (AKI) and acute-on-chronic renal failure (ACRF) are surprisingly sparse and confounded by differences in definition. Reported incidences vary, with few studies being population-based. Given this and our aging population, the incidence of AKI may be much higher than currently thought. We tested the hypothesis that the incidence is higher by including all patients with AKI (in a geographical population base of 523,390) regardless of whether they required renal replacement therapy irrespective of the hospital setting in which they were treated. We also tested the hypothesis that the Risk, Injury, Failure, Loss, and End-Stage Kidney (RIFLE) classification predicts outcomes. We identified all patients with serum creatinine concentrations $\geq 150 \mu\text{mol/L}$ (male) or $\geq 130 \mu\text{mol/L}$ (female) over a 6-mo period in 2003. Clinical outcomes were obtained from each patient's case records. The incidences of AKI and ACRF were 1811 and 336 per million population, respectively. Median age was 76 yr for AKI and 80.5 yr for ACRF. Sepsis was a precipitating factor in 47% of patients. The RIFLE classification was useful for predicting full recovery of renal function ($P < 0.001$), renal replacement therapy requirement ($P < 0.001$), length of hospital stay [excluding those who died during admission ($P < 0.001$)], and in-hospital mortality ($P = 0.035$). RIFLE did not predict mortality at 90 d or 6 mo. Thus the incidence of AKI is much higher than previously thought, with implications for service planning and providing information to colleagues about methods to prevent deterioration of renal function. The RIFLE classification is useful for identifying patients at greatest risk of adverse short-term outcomes.

J Am Soc Nephrol 18: 1292–1298, 2007. doi: 10.1681/ASN.2006070756

Epidemiologic studies of acute kidney injury (AKI) and acute-on-chronic renal failure (ACRF), particularly early AKI that does not require renal replacement therapy (RRT), are surprisingly sparse and bedevilled by differences in definition, making incidence, prevalence, and particularly outcomes difficult to compare. AKI is managed by a variety of specialities, renal wards, high-dependency wards, and intensive care units (ICU). A number of studies included ICU-treated patients (1–4); others included only those with severe AKI (5,6) or included only those who required RRT (6–8). Because AKI occurs more frequently in older people, the incidence of this condition is rising in accordance with demographic trends. Reported incidences vary from 140 to 620 per million population (pmp) (5,6,9–11), but only some studies are population based. It therefore may be that the incidence is much higher than current estimates, with major implications for service planning. Because AKI is associated with high mortality and treatment with RRT is costly, in the many hospital settings in which it occurs, we must identify patients early and intervene to avoid RRT. The need for adequate definitions and epidemiologic studies has never been greater.

This paper provides data that indicate a significantly higher incidence of acute kidney injury in the general population than previously estimated, particularly in older people, and confirms the utility of the RIFLE classification in predicting outcomes. It relates to a Mini-Review in the March issue of CJASN by Jo et al. (pages 356–365) on the use of drugs in managing acute kidney injury.

The International Acute Dialysis Quality Initiative (ADQI) (12) group suggested RIFLE (risk, injury, failure, loss, ESRD) classification for AKI and ACRF (Table 1) and suggested that this should be tested in large data sets. No population-based studies have been carried out to test the ability of this classification to predict outcomes.

We aimed to determine the incidence and factors that affect the development and outcomes of AKI and ACRF in a defined population that included patients who had or had not required RRT and irrespective of the hospital setting in which they were treated. We aimed to test the hypotheses that the incidence of AKI and ACRF is much higher than previously estimated and that the RIFLE classification predicts short- and long-term outcomes.

Materials and Methods

We carried out a retrospective cohort study in the Grampian region of Scotland (population 523,390). There are 3 hospitals in this area and 2 biochemistry laboratories, which are electronically linked.

For the purpose of this study, we defined a “threshold” serum

Received July 19, 2006. Accepted January 3, 2007.

Published online ahead of print. Publication date available at www.jasn.org.

Address correspondence to: Dr. Tariq Zulfiqar Ali, Ward 25, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN UK. Phone: +44-1224-55-2139; Fax: +44-1224-55-1134; E-mail: tariq.ali@nhs.net

Table 1. RIFLE classification^a

Category	GFR Criteria	UO Criteria
Risk (R)	Increased creatinine $\times 1.5$ or GFR \downarrow by 25%	UO < 0.5 ml/kg per h $\times 6$ h
Injury (I)	Increased creatinine $\times 2$ or GFR \downarrow by 50%	UO < 0.5 ml/kg per h $\times 12$ h
Failure (F)	Increased creatinine $\times 3$ or GFR \downarrow by 75% or creatinine ≥ 350 $\mu\text{mol/L}$ (rise at least 44 $\mu\text{mol/L}$)	UO < 0.3 ml/kg per h $\times 24$ h or anuria $\times 12$ h
Loss (L)	Persistent AKI > 4 wk	
ESRD (E)	ESRD > 3 mo	

^aAKI, acute kidney injury; RIFLE, risk, injury, failure, loss, ESRD; UO, urine output.

creatinine value of 150 $\mu\text{mol/L}$ in men or 130 $\mu\text{mol/L}$ in women. We identified all adult patients (> 15 yr old) with serum creatinine value more than or equal to the threshold during a 6-mo period (January 1, 2003, through June 30, 2003). This serum creatinine value was termed the “index creatinine.” Using the abbreviated Modification of Diet in Renal Disease (MDRD) equation (13,14), we estimated the GFR and applied the RIFLE classification (Table 1). We used the rise in serum creatinine concentration or fall in GFR (whichever was greater) to assign a category in the RIFLE classification; we did not use urine output as a criterion for classification, because it was not possible to obtain accurate records of urine output. We studied the R, I, and F categories; the last 2 categories (L and E) are clinical outcomes.

AKI Group

When serum creatinine had been measured in the 6 mo before the date of index creatinine, this was taken as baseline creatinine. Patients were classified as having AKI when baseline serum creatinine was below the threshold and subsequently rose by a factor of 1.5 or more or the GFR was reduced by 25% or more. We also noted the highest serum creatinine that the patient had had during the episode of AKI (“maximum creatinine”). When a baseline serum creatinine was not available but creatinine subsequently fell from the maximum creatinine by a factor of 1.5 or more to a value below threshold, these patients were also defined as having AKI.

Patients were excluded when baseline was not available and the patient died before renal recovery. They also were excluded when creatinine rise was less than a factor of 1.5 or rise was not sustained for 24 h.

ACRF Group

The ADQI group recommends separate criteria for the diagnosis of ACRF. They assigned these patients to the Fc category (where F is failure and c is CKD) when their serum creatinine had increased to 350 $\mu\text{mol/L}$. The ADQI group did not assign a category to those in whom serum creatinine did not rise as high as 350 $\mu\text{mol/L}$.

Patients in our study were defined as having chronic kidney disease (CKD) when they had three creatinine values that were above threshold before the index creatinine and each value was separated by at least 1 mo. Biochemistry database was searched from 1996 onward to obtain serum creatinine values to define CKD.

We used the following classification of ACRF in this study:

1. Risk (R-ACRF): serum creatinine had risen by a factor of 1.5 or more from the baseline or GFR reduced by 25% or more but serum creatinine had not reached 350 $\mu\text{mol/L}$.

2. Injury (I-ACRF): serum creatinine had risen by a factor of 2 or more, or GFR reduction was 50% or more but serum creatinine had not reached 350 $\mu\text{mol/L}$.
3. Fc: according to the recommendations made by ADQI (as described previously).

Patients were excluded when the rise in serum creatinine was less than a factor of 1.5 or any rise was not sustained for 24 h.

Renal Recovery (Definitions)

1. Full recovery: Serum creatinine concentrations fell below threshold (or fell to the baseline in cases of ACRF).
2. Partial recovery: Serum creatinine remained above the threshold (or remained above the baseline in cases of ACRF).
3. Failure to recover: Dialysis dependent at 90 d.

Data Collection

Data including demographic details, background comorbid conditions, precipitating factors, duration of hospital stay, requirement for and mode of RRT, and date of death were extracted from patient records. Patients were classified into low-, medium-, and high-risk categories using the Khan index (15) (low risk: Age < 70 and no comorbid illness; medium risk: Age > 70 and < 80 , or age < 80 with one comorbid illness, or age < 70 with diabetes; high risk: Age > 80 , or any age with two or more comorbidities, or any age with malignancy).

Statistical Analyses

Data were analyzed using SPSS (Release 14.0.0; SPSS, Chicago, IL). For categorical variables, groups were compared using the χ^2 test or Fisher exact test when expected values of < 5 were obtained. For age and duration of hospital stay, group medians were compared using Mann-Whitney *U* tests (between AKI and ACRF) or Kruskal-Wallis tests (among R, I, and F categories and among Khan’s index low, medium, and high categories).

Results

Demographics and Comparison of AKI and ACRF Groups

A total of 5321 patients were identified as having a creatinine that was more than or equal to the threshold value. A total of 474 patients were classified as having AKI, and 88 were classified as having ACRF. This equates to an annual incidence of 1811 and 336 pmp, respectively. The breakdown of the groups is shown in Figure 1.

A total of 393 (83%) of those with AKI had a baseline creatinine value available on the biochemistry database. A total of 81




Figure 1. Group distribution. ACRF, acute or chronic renal failure; AKI, acute kidney injury; CKD, chronic kidney disease; unclassified, either with insufficient creatinine values for the classification of CKD or fluctuating levels of creatinine values without evidence of AKI/ACRF; visitors, patients who were not from the Grampian area but happened to be in this area at the time of index creatinine.

(17%) patients did not have a baseline creatinine available, but, after recovering from AKI, their creatinine both fell by a factor of at least 1.5 and fell below our threshold value.

Patients in the ACRF group were older than those with AKI ($P = 0.003$). Renal imaging was performed more often in the ACRF group ($P < 0.001$), and a greater proportion of patients were treated by nephrologists in this group ($P < 0.001$). Median duration of stay in hospital was longer in the AKI than in the ACRF group ($P = 0.009$). A significantly greater proportion of patients had full recovery of renal function in the AKI group ($P < 0.001$). There were no significant differences in gender, RRT requirement, and mortality (in-hospital and 90 d) between the two groups. Most patients in both groups were in the high-risk category using Khan's index. Only 45 (9.5%) patients with AKI and 3 (3.4%) patients with ACRF were treated in the ICU (Table 2).

Table 3. Comorbid conditions^a

Condition	Total (%) ^b	AKI (%)	ACRF (%)	<i>P</i>
IHD	31.5	29.5	42	0.028
Hypertension	27.8	27.2	30.7	0.591
Malignancy	22.5	21.7	25	0.591
CVD	17.1	17.3	15.9	0.870
Diabetes	15.7	15	19.3	0.385
Cardiac failure	13.2	12.9	14.8	0.754
None	15.7	16.0	13.6	0.683
PVD	7.7	6.8	12.5	0.100
COPD	7.7	7.8	6.8	0.919
Liver disease	2.8	3.0	2.3	1.000
CT disease	2.3	2.5	1.1	0.703
Comorbid sum ^c				0.173 ^d
0	15.7	16.0	13.6	
1	42.2	43.2	36.4	
2	24.2	24.3	23.9	
≥3	18.0	16.5	26.1	

^aCOPD, chronic obstructive airway disease; CT, connective tissue; CVD, cerebrovascular disease; IHD, ischemic heart disease; PVD, peripheral vascular disease.

^bARF + ACRF.

^cNumber of comorbid conditions in a patient.

^d χ^2 for all groups = 4.982, df = 3, $P = 0.173$.

Precipitating Factors and Comorbid Conditions

Sepsis was the most frequent precipitating factor (47%) followed by hypovolemia (32%). A total of 39% had more than one precipitating factor for the development of AKI and ACRF. Comorbidities are shown in Table 3.

Outcomes

Mortality. Mortality rose to 50% by 6 mo in those with AKI and to 63% in those with ACRF (Table 2). Significantly more

Table 2. Demographics and comparison of AKI and ACRF groups^a

Characteristics	AKI	ACRF	<i>P</i>
Total	474	88	
Age (yr; median [IQR])	76.0 (66.9 to 83.9)	80.5 (74.5 to 84.9)	0.003
Incidence (pmp/yr)	1811	336	<0.001
Male (<i>n</i> [%])	254 (53.6)	50 (56.8)	0.658
Renal imaging done (<i>n</i> [%])	227 (47.9)	67 (76.1)	<0.001
RRT received (<i>n</i> [%])	37 (7.8)	11 (12.5)	0.203
Treated by nephrologists (<i>n</i> [%])	119 (25.1)	45 (51.1)	<0.001
Full renal recovery (<i>n</i> [%])	321 (67.7)	31 (35.2)	<0.001
In-hospital mortality (<i>n</i> [%])	155 (32.7)	35 (39.8)	0.244
90-d mortality (<i>n</i> [%])	196 (41.4)	43 (48.9)	0.233
6-mo mortality (<i>n</i> [%])	236 (49.8)	55 (62.5)	0.038
Median duration of stay (d; median [IQR])	17.0 (9.0 to 33.0)	12.5 (5.3 to 26.0)	0.009

^aAKI, acute kidney injury; ACRF, acute or chronic renal failure; IQR, interquartile range; pmp, per million population; RRT, renal replacement therapy.

patients died during hospital admission in the F category of the AKI group ($P = 0.035$) (Table 4; Figure 2). Mortality (except at 6 mo) was not significantly different across RIFLE-ACRF categories (Table 4).

In those with AKI, 26% of the low-risk group died, and mortality increased to 42% in the medium-risk and 56% in the high-risk groups at 6 mo. Overall, there was a highly significant association between Khan's index and mortality at 6 mo ($P < 0.001$; Table 5). A similar trend was observed among patients with ACRF, with mortalities of 0 (there were only four patients in the low-risk group), 56, and 68%, respectively, for those in the ACRF group ($P = 0.016$).

Renal Recovery. Full renal recovery was achieved in 321 (68%) of those in the AKI group; 24 (5%) partially recovered, and in 127 (27%), recovery could not be determined because the patient died in the acute phase. Recovery in the F category was significantly lower ($P < 0.001$). Only two patients remained on dialysis for >90 d. After exclusion of the 127 patients in whom it was not possible to determine the recovery because they died in the acute phase of their illness, 92.5% had full renal recovery, 7% had partial recovery, and 0.6% had no recovery.

In contrast, in the ACRF group, full recovery was achieved in only 31 (35%), partial recovery was achieved in 14 (16%), and 40 (45%) patients died in the acute phase. No significant differences were observed in the proportions with full recovery across the RIFLE-ACRF categories (Table 4); three patients had no recovery of their renal function. After exclusion of the 40 patients in whom it was not possible to determine recovery, 65% had full recovery, 29% had partially recovery, and 6% had no recovery.

Patients Who Received RRT. Thirty-seven (8%) patients with AKI received RRT; 23 (62%) of these had their first dialysis in the ICU, 13 (35%) in the renal unit, and one in a surgical high-dependency unit. Nineteen (51%) had hemodialysis and 18 (49%) had hemofiltration as the first mode of RRT. Twenty-one (57%) of those who received RRT died. Only two patients were on RRT at 90 d. Most patients who received RRT were in the F category ($P < 0.001$).

Eleven (13%) of those in the ACRF group received RRT. Nine (82%) patients received dialysis in the renal unit, one in the ICU, and one in a coronary care unit. Ten received hemodialysis and one received hemofiltration; five (45%) of those who received RRT had died by 6 mo. Most patients who received RRT were in the Fc category.

Referral to Nephrologists. Only 25% of those in the AKI group were referred to a nephrologist. A significantly greater proportion of patients were referred from the F category ($P < 0.001$). In contrast, 51% of the ACRF group were referred, and there were no significant differences in the rates of referral between RIFLE-ACRF categories (Table 4).

Duration of Hospital Stay. The median duration of stay for AKI was 17 d; this was significantly shorter in the R category ($P = 0.047$). However, among those who survived to leave the hospital, the duration of stay increased across RIFLE categories, being longest in F ($P = 0.001$). Median duration of stay was difficult to interpret in the ACRF group because of the small number in the R and I categories, especially after exclu-

Table 4. AKI and ACRF outcomes: Effect of RIFLE

Characteristic	AKI Group					ACRF Group				
	All	R	I	F	P	All	R-ACRF	I-ACRF	Fc	P
<i>n</i>	474	105	233	136		88	12	18	58	
In-hospital mortality (<i>n</i> [%])	155 (33)	28 (27)	71 (30)	56 (41)	0.035	35 (40)	3 (25)	8 (44)	24 (41)	0.517
90 d mortality (<i>n</i> [%])	196 (41)	37 (35)	94 (40)	65 (48)	0.132	43 (49)	4 (33)	11 (61)	28 (48)	0.325
6-mo mortality (<i>n</i> [%])	236 (50)	48 (46)	112 (48)	76 (56)	0.224	55 (63)	4 (33)	14 (78)	37 (64)	0.045
Full renal recovery (<i>n</i> [%])	321 (68)	75 (71)	176 (75)	70 (51)	<0.001	31 (35)	6 (50)	9 (50)	16 (28)	0.113
RRT required (<i>n</i> [%])	37 (8)	1 (1)	7 (3)	29 (21)	<0.001	11 (13)	0 (0)	1 (6)	10 (18)	0.150
Referred to nephrologist (<i>n</i> [%])	119 (25)	15 (14)	41 (18)	63 (46)	<0.001	45 (51)	8 (67)	6 (33)	31 (53)	0.168
RRT received among referred (<i>n</i> [%])	36 (30)	1 (7)	7 (17)	28 (44)	0.001	10 (22)	0 (0)	1 (17)	9 (29)	0.222
RRT received among not referred (<i>n</i> [%])	1 (0.3)	0 (0)	0 (0)	1 (1)	0.206	1 (2)	0 (0)	0 (0)	1 (4)	1.000
Hospital stay (d; median [IQR])	17.0 (9.0 to 33.0)	13.0 (7.5 to 28.0)	18.5 (9.0 to 33.0)	18.5 (9.0 to 40.8)	0.047	12.5 (5.3 to 26.0)	21.0 (14.0 to 25.8)	8.0 (2.0 to 21.3)	12.0 (5.8 to 27.5)	0.067
Hospital stay (d; median [IQR]) ^a	19.0 (10.0 to 33.0)	12.5 (7.3 to 26.8)	19.0 (12.0 to 34.0)	24.5 (13.3 to 45.5)	0.001	15.5 (8.3 to 26.0)	21.0 (15.0 to 24.0)	13.0 (3.5 to 24.0)	14.0 (7.5 to 26.3)	0.486

^aExcluding those who died during admission.




Figure 2. Percentage of mortality among patients with AKI by RIFLE (risk, injury, failure, loss, ESRD) categories.

sion of patients who died. There were no significant differences in the duration of stay across RIFLE-ACRF categories (Table 4).

Discussion

This is the first study to define the incidence of AKI and ACRF in a defined geographic population base, regardless of whether RRT was required and irrespective of where treatment took place. The combined annual incidence of AKI and ACRF was 2147 pmp, very much higher than all previous published estimates. The RIFLE classification predicted the probability of making a full renal recovery, the need for RRT, the length of hospital stay, and in-hospital mortality. It did not, however, predict the long-term outcomes of mortality at 90 d and 6 mo.

In a Spanish study (10), the incidence of AKI was calculated at 209 pmp/yr; patients who were treated in tertiary care hospitals with a serum creatinine $>177 \mu\text{mol/L}$ were included. Retrospective studies in the UK reported an incidence in those with a serum creatinine $\geq 300 \mu\text{mol/L}$ of 620 pmp/yr (6) and 140 pmp/yr in those with serum creatinine $>500 \mu\text{mol/L}$ (9). In a prospective study in England, which, unlike those quoted previously included patients with ACRF, the incidence was 545 pmp/yr in those with serum creatinine of $>300 \mu\text{mol/L}$ (5). The incidence in this study is higher, probably reflecting the

lower serum creatinine value for entry and that all patients in a defined geographic area were included. The incidence rate in the Spanish study is lower than in all of the UK studies despite its lower serum creatinine value at entry, possibly because many patients may have been treated in hospitals other than the tertiary care hospitals or because there may be a lower incidence of acute renal failure in Spain. A recent large study from the United States gave an incidence of 288 pmp, although this was based on *International Classification of Diseases, Ninth Revision* coding at discharge rather than on creatinine values (11). The age distribution of the United Kingdom is similar to that in Spain, with approximately 16% of the population older than 65 yr; it is slightly lower in the United States (12.4%) (16), although not sufficient to explain the difference in incidence. The reported incidence of AKI in the literature therefore varies considerably and depends on how AKI is defined, whether ACRF is included, and whether all patients in the population studied are included. In our population-based study, the incidence is much higher, with important implications for service planning.

The mean age in the study by Liano and Pascual (10) was 64, in the study by Stevens *et al.* was 73 (5) and in an American ICU-based study was 67 (17). Waikar *et al.* (11) reported median age in patients who were identified between 1998 and 2002 as 72; patients in our study had a median age of 77, and this was higher in those with ACRF. In a previous study, the median age in those who required RRT was reported to be 65.8 yr in AKI and 74.9 in ACRF (8). The high median age in our study reflects inclusion of all patients with AKI or ACRF regardless whether they needed RRT or whether they were cared for in the ICU. AKI and ACRF are emerging as diseases of the elderly; therefore, their incidence is likely to continue to rise.

Sepsis was the most frequent precipitating factor (47%) for AKI in our study, similar to the findings of others (8,11,18). We also found that $>80\%$ of patients had at least one comorbid illness and that the majority, approximately 70% of patients with AKI, were in the high-risk group. This is slightly higher than the 65% (of 310 patients) in the high-risk group in a study in the same geographic area in 1989 to 1990, although, in that study, the entry criterion

Table 5. AKI outcomes: Effect of comorbidities (Khan's index)

Characteristic	All	Risk			P
		Low	Medium	High	
n	474	39	118	317	
Median age (yr; median [IQR])	76.0 (66.9 to 83.9)	58.2 (46.1 to 65.0)	72.5 (64.9 to 75.0)	81.8 (72.5 to 87.0)	<0.001
Men in risk category (n [%])	254 (54)	26 (67)	74 (63)	154 (49)	0.007
In-hospital mortality (n [%])	155 (33)	8 (20)	41 (35)	106 (33)	0.234
90-d mortality (n [%])	196 (41)	10 (26)	43 (36)	143 (45)	0.031
6-mo mortality (n [%])	236 (50)	10 (26)	49 (42)	177 (56)	<0.001
Full recovery (n [%])	321 (68)	28 (72)	73 (62)	220 (69)	0.289
RRT required (n [%])	37 (8)	10 (26)	13 (11)	14 (4)	<0.001
Referred to nephrologist (n [%])	119 (25)	22 (56)	42 (36)	55 (17)	<0.001
Hospital stay (d; median [IQR])	17.0 (9.0 to 33.0)	17.0 (9.0 to 23.0)	17.0 (8.0 to 30.0)	18.0 (9.0 to 33.5)	0.637
Hospital stay (d; median [IQR]) ^a	19.0 (10.0 to 33.0)	18.0 (9.0 to 35.0)	17.0 (11.0 to 28.0)	20.0 (9.0 to 36.0)	0.784

^aExcluding those who died during admission.

was a serum creatinine ≥ 300 $\mu\text{mol/L}$ (6). Another study of patients with AKI with no other organ failure and a serum creatinine ≥ 500 $\mu\text{mol/L}$ that was known to renal or ICU staff found that 46% were in the high-risk group (19). The differences among studies may in part reflect the serum creatinine value at entry, whether patients had single or multiple organ failure, or whether only those who were referred to a nephrologist were included. The proportion of patients who have AKI/ACRF and are elderly and/or have significant comorbidity, however, is high. The absolute numbers of such patients are increasing along with the technical ability to treat them. In addition to standardizing the definition of AKI and data collection methods, we must determine the need for and appropriate use of critical care resources for this group of patients.

A recent survey in Europe showed that the RIFLE classification is being used more commonly (20). Two studies (21,22) showed a higher number of patients in the F category than ours, but both of these were in an ICU setting, where more advanced AKI would be expected. This study differs from all others by including patients who were identified from a single biochemistry laboratory database that serves the whole population and setting a relatively low threshold creatinine value for entry. However, if patients' creatinine values had never risen above this threshold during the 6-mo identification period (*i.e.*, those with very mild AKI), then they would have been excluded from our study. This may explain why the number of patients in the R category was lower than that in the I category. An ICU-based study in the United Kingdom showed similar percentages in R and I categories (22), and another study found that $<10\%$ were in the R category, but that study was restricted to those who required RRT in the ICU (21). Therefore the percentages in each category will vary with the question being posed by the investigator and the patient group being studied.

A systematic review reported overall mortality of 50% in various groups of patients who had AKI and were measured at various time points (23). The mortality figures in our study are consistent with those of Stevens *et al.* (5). In our study, the RIFLE classification was able to predict in-hospital mortality but not mortality at 90 d or 6 mo. In contrast, comorbid conditions predicted mortality at 90 d and 6 mo but not mortality that occurred in hospital, showing that the severity of renal impairment predicts early and comorbidity predicts later mortality.

RRT requirement was significantly higher in those in the F group than in the R and I groups ($P < 0.001$); this was also found in the ICU-based studies in the United Kingdom (22) and Sweden (21). Although the referral rate was higher in F, this did not completely explain the higher rates of RRT that were observed in the F category—considering only those who were referred, there was a much higher likelihood of receiving RRT when they were in the F category than in the R or I categories (Table 4).

When the patients who died in hospital were excluded, full recovery of renal function was very high in those with AKI (92.5%). This is likely to reflect that almost all of the precipitating factors for AKI in this group of patients would have led to acute tubular necrosis, which then recovered irrespective of its severity, making it inappropriate to apply the RIFLE classification to this outcome. In contrast, creatinine values were re-

duced to previous levels in only 65% of those who had background CKD and survived their acute illness. Few studies have reported renal recovery in patients with AKI, but some, such as ours, have shown that the majority will recover sufficient renal function (24).

Median duration of stay in this study was shorter than in two ICU-based studies (16,25) in which the patients were likely to have been more severely ill. It was closer to that in a study of patients who required RRT and were treated in all hospital environments (8). In our study, the RIFLE classification was able to predict length of stay, making it useful for service planning.

For the binary outcomes, logistic regression was used to adjust for the possible confounding factors: age, gender, and comorbidities. RIFLE was still found to be significantly associated with in-hospital mortality, full renal recovery, need for RRT, and referral.

In this study, the numbers with ACRF were small and association between categories and outcomes (except 6-mo mortality) could not be demonstrated. There were only 58 patients in the Fc group, although this number was increased by 30 using our wider definition of ACRF. We still may have missed a significant number of patients because those with background CKD would require a considerable increase in creatinine to enter this classification (*e.g.*, a baseline creatinine of 200 $\mu\text{mol/L}$ requires a rise to 300 $\mu\text{mol/L}$ for entry into the R category). Appropriate criteria for ACRF therefore requires more discussion and possibly further studies.

Conclusion

This population-based study showed that incidence of AKI is much higher than previously thought, with important implications for service planning and the provision of information to colleagues so that early action can be taken to prevent deterioration of renal function. We also defined a population group in which early interventions can be tested. The RIFLE classification was useful for predicting in-hospital mortality, the need for RRT, the length of hospital stay, and the likelihood of recovery of renal function but not survival at 90 d or 6 mo. This classification therefore should be used to identify the patients who are at greatest risk for adverse short-term outcomes.

Acknowledgments

We thank Kidney Research UK for funding this project. Part of this research was presented at the Renal Association (May 3 to 5, 2006; UK) and at the European Renal Association meeting (July 15 to 18; 2006).

We are grateful to Alan Broad for setting up the database and Carol Ritchie for all her hard work throughout the process.

Disclosures

None.

References

1. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM; Program to Improve Care in Acute Renal Disease: Spectrum of acute renal failure in the intensive care unit: The PICARD experience. *Kidney Int* 66: 1613–1621, 2004

2. Carbonell N, Blasco M, Sanjuan R, Garcia-Ramon R, Blanquer J, Carrasco AM: Acute renal failure in critically ill patients: A prospective epidemiological study. *Nefrologia* 24: 47–53, 2004
3. Bahloul M, Ben Hamida C, Damak H, Kallel H, Ksibi H, Rekek N, Chelly H, Bouaziz M: Incidence and prognosis of acute renal failure in the intensive care unit: Retrospective study of 216 cases. *Tunis Med* 81: 250–257, 2003
4. Cole L, Bellomo R, Silvester W, Reeves JH: A prospective, multicenter study of the epidemiology, management, and outcome of severe acute renal failure in a “closed” ICU system. *Am J Respir Crit Care Med* 162: 191–196, 2000
5. Stevens PE, Tamimi NA, Al-Hasani MK, Mikhail AI, Kearney E, Lapworth R, Prosser DI, Carmichael P: Non-specialist management of acute renal failure. *QJM* 94: 533–540, 2001
6. Khan IH, Catto GR, Edward N, Macleod AM: Acute renal failure: Factors influencing nephrology referral and outcome. *QJM* 90: 781–785, 1997
7. Firmat J, Zucchini A, Martin R, Aguirre C: A study of 500 cases of acute renal failure (1978–1991). *Ren Fail* 16: 91–99, 1994
8. Metcalfe W, Simpson M, Khan IH, Prescott GJ, Simpson K, Smith WC, MacLeod AM, Scottish Renal Registry: Acute renal failure requiring renal replacement therapy: Incidence and outcome. *QJM* 95: 579–583, 2002
9. Feest TG, Round A, Hamad S: Incidence of severe acute renal failure in adults: Results of a community based study. *BMJ* 306: 481–483, 1993
10. Liano F, Pascual J: Epidemiology of acute renal failure: A prospective, multicenter, community-based study. Madrid Acute Renal Failure study group. *Kidney Int* 50: 811–818, 1996
11. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM: Declining mortality in patients with acute renal failure, 1988 to 2002. *J Am Soc Nephrol* 17: 1143–1150, 2006
12. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup: Acute renal failure: Definition, outcome measures, animal models, fluid therapy and information technology needs—The second international consensus conference of the acute dialysis quality initiative (ADQI) group. *Crit Care* 8: R204–R212, 2004
13. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S: Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? Modification of Diet in Renal Disease study group. *J Am Soc Nephrol* 10: 2426–2439, 1999
14. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *Am J Kidney Dis* 39[Suppl 1]: S1–266, 2002
15. Khan IH, Catto GR, Edward N, Fleming LW, Henderson IS, MacLeod AM: Influence of coexisting disease on survival on renal-replacement therapy. *Lancet* 341: 415–418, 1993
16. OECD Factbook 2006: Economic, Environmental and Social Statistics. Available at: <http://titania.sourceoecd.org/vl=18885718/cl=14/nw=1/rpsv/factbook/data/01-02-01-t01.xls>
17. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: A multinational, multicenter study. *JAMA* 294: 813–818, 2005
18. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ: Acute renal failure in intensive care units: Causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. *Crit Care Med* 24: 192–198, 1996
19. Hegarty J, Middleton RJ, Krebs M, Hussain H, Cheung C, Ledson T, Hutchison AJ, Kalra PA, Rayner HC, Stevens PE, O’Donoghue DJ: Severe acute renal failure in adults: Place of care, incidence and outcomes. *QJM* 98: 661–666, 2005
20. Ricci Z, Ronco C, D’Amico G, De Felice R, Rossi S, Bolgan I, Bonello M, Zamperetti N, Petras D, Salvatori G, Dan M, Piccinni P: Practice patterns in the management of acute renal failure in the critically ill patient: An international survey. *Nephrol Dial Transplant* 21: 690–696, 2006
21. Bell M, Liljestam E, Granath F, Fryckstedt J, Ekblom A, Martling CR: Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. *Nephrol Dial Transplant* 20: 354–360, 2005
22. Abosaif NY, Tolba YA, Heap M, Russell J, El Nahas AM: The outcome of acute renal failure in the intensive care unit according to RIFLE: Model application, sensitivity, and predictability. *Am J Kidney Dis* 46: 1038–1048, 2005
23. Ympa YP, Sakr Y, Reinhart K, Vincent JL: Has mortality from acute renal failure decreased? A systematic review of the literature. *Am J Med* 118: 827–832, 2005
24. Schiffl H: Renal recovery from acute tubular necrosis requiring renal replacement therapy: A prospective study in critically ill patients. *Nephrol Dial Transplant* 21: 1248–1252, 2006
25. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA: Acute renal failure in patients with sepsis in a surgical ICU: Predictive factors, incidence, comorbidity, and outcome. *J Am Soc Nephrol* 14: 1022–1030, 2003

**Access to UpToDate on-line is available for additional clinical information
at <http://www.jasn.org/>**